CA3196153A1 - Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals - Google Patents

Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals

Info

Publication number
CA3196153A1
CA3196153A1 CA3196153A CA3196153A CA3196153A1 CA 3196153 A1 CA3196153 A1 CA 3196153A1 CA 3196153 A CA3196153 A CA 3196153A CA 3196153 A CA3196153 A CA 3196153A CA 3196153 A1 CA3196153 A1 CA 3196153A1
Authority
CA
Canada
Prior art keywords
compound
substituted
unsubstituted
disease
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196153A
Other languages
English (en)
French (fr)
Inventor
Lee Fader
Jason Burch
Miguel St-Onge
Stephane Dorich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventus Therapeutics US Inc
Original Assignee
Ventus Therapeutics US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics US Inc filed Critical Ventus Therapeutics US Inc
Publication of CA3196153A1 publication Critical patent/CA3196153A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3196153A 2020-09-24 2021-09-23 Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals Pending CA3196153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082695P 2020-09-24 2020-09-24
US63/082,695 2020-09-24
PCT/US2021/051670 WO2022066851A1 (en) 2020-09-24 2021-09-23 PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Publications (1)

Publication Number Publication Date
CA3196153A1 true CA3196153A1 (en) 2022-03-31

Family

ID=80846865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196153A Pending CA3196153A1 (en) 2020-09-24 2021-09-23 Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals

Country Status (7)

Country Link
US (1) US20240018138A1 (cg-RX-API-DMAC7.html)
EP (1) EP4216940A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543254A (cg-RX-API-DMAC7.html)
CN (1) CN116209442A (cg-RX-API-DMAC7.html)
AU (1) AU2021349249A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196153A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022066851A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124665A (ko) 2020-12-22 2023-08-25 노파르티스 아게 Cgas 관련 병태의 치료에 유용한 인돌 유도체
WO2023183275A1 (en) * 2022-03-22 2023-09-28 Ventus Therapeutics U.S., Inc. Hexahydropyrido[4,3-b]indolyl ketone derivatives useful as cgas modulators
CN121248633A (zh) * 2022-11-09 2026-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的环状苯并咪唑衍生物
CN120769854A (zh) * 2022-12-21 2025-10-10 伊莱利利公司 氮杂䓬并[4,5-B]吲哚酮cGAS抑制剂
AR133584A1 (es) 2023-08-18 2025-10-15 Univ Leuven Kath Nuevos compuestos
CN119490508A (zh) * 2023-08-21 2025-02-21 上海交通大学 一类螺环四氢-γ-咔啉衍生物的制备方法以及应用
WO2025218659A1 (en) * 2024-04-16 2025-10-23 Insilico Medicine Ip Limited Novel compounds as cyclic gmp-amp synthase inhibitor and uses thereof
WO2026026969A1 (zh) * 2024-08-01 2026-02-05 杭州英创医药科技有限公司 作为cGAS抑制剂的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011019417A1 (en) * 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
JP2021506862A (ja) * 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Tlr7/8アンタゴニストおよびそれらの使用
MX2020008237A (es) * 2018-02-05 2020-09-25 Univ Rockefeller Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
WO2020142729A1 (en) * 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents
WO2020186027A1 (en) * 2019-03-13 2020-09-17 Daisuke Tomita Inhibitors of cgas for treating autoinflammatory diseases and cancer metastasis

Also Published As

Publication number Publication date
JP2023543254A (ja) 2023-10-13
US20240018138A1 (en) 2024-01-18
WO2022066851A1 (en) 2022-03-31
AU2021349249A1 (en) 2023-04-13
EP4216940A1 (en) 2023-08-02
EP4216940A4 (en) 2025-01-01
CN116209442A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
CN113286794B (zh) Kras突变蛋白抑制剂
WO2022066851A1 (en) PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
CN112638380B (zh) 小脑蛋白(crbn)配体
CN116390923B (zh) 杂环类衍生物及其制备方法和用途
JP7711073B2 (ja) 免疫抑制剤として有用な大環状pad4阻害剤
JP2021535909A (ja) 高活性stingタンパク質アゴニスト化合物
EP3917926B1 (en) Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
KR101272263B1 (ko) 감염 방지제로서 사용되는8-메톡시-9h-이소티아졸로[5,4-b]퀴놀린-3,4-디온 및관련 화합물
AU2012293618B2 (en) Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones
CN114641472A (zh) 用于治疗疾病的双亮氨酸拉链(dlk)激酶的双环[1.1.1]戊烷抑制剂
US11858938B2 (en) Imidazo-fused heterocycles and uses thereof
CN119173505A (zh) 抗病毒杂环化合物
AU2023254925A1 (en) Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors
WO2023143249A1 (zh) 靶向malt1的蛋白降解化合物
JP2018531993A (ja) Alkおよびsrpk阻害剤ならびに使用方法
KR20240121746A (ko) 테트라하이드로피리다진, 이를 포함하는 조성물, 및 이의 용도
RS55201B1 (sr) Antimalarijski agensi
CA3087926A1 (en) Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
WO2021233394A1 (en) Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas
WO2016196910A1 (en) Compounds for the modulation of myc activity
US20240132464A1 (en) Heterocyclic compounds as e3 ligase inhibitors
HK40093069A (en) Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
US20210221820A1 (en) Compounds for the modulation of myc activity
WO2024207131A1 (en) Ferroptosis inhibitors–phenoxazine acetamides

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260310

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260323

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260709